Furthermore, it became clear that modulation of sclerostin concentration and activity affects bone mass, as indicated by the fact that SOST SNVs are associated with BMD (131) and that heterozygous carriers for mutations causing sclerosteosis and van Buchem disease also show an increased bone mass (132). Here, SOST is linked to hyperostosis corticalis generalisata.